Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials

The assessment of systemic lupus erythematosus (SLE) disease activity in clinical trials has been challenging. This is related to the wide spectrum of SLE manifestations and the heterogeneity of the disease trajectory. Currently, composite outcome measures are most commonly used as a primary endpoint while organ-specific measures are often used as secondary outcomes. In this article, we review the outcome measures and endpoints used in most recent clinical trials and explore potential avenues for further development of new measures and the refinement of existing tools.
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Source Type: research